Pfizer Ltd. — Regulatory Filings 2021

Jul 28, 2021

Pfizer Limited

The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

July 28, 2021

The Corporate Relationship Dept. BSE Limited 1st Floor, P.J.Towers Dalal Street, Fort Mumbai - 400 001 Scrip Code: 500680

The Manager, Listing Dept. The National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051 Scrip Symbol: PFIZER

Dear Sirs,

Sub: Unaudited financial results for the quarter ended June 30, 2021.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the unaudited financial results for the quarter ended June 30, 2021, which were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 11.30 a.m. and concluded at 2.00 p.m.

Also please find enclosed the Limited Review Report by our Auditors M/s. Walker Chandiok & Co LLP, in respect of the above results.

Please take the above on record.

Thanking you,

Yours truly,

For Pfizer Limited

Prajeet Nair Company Secretary

Encl: A/a

Cc: National Securities Depository Limited (NSDL) Central Depository Services (India) Limited (CDSL) Kfin Technologies Private Limited

CIN: L24231MH1950PLC008311 Email ID: contactus.india@pfizer.com Website: www.pfizerindia.com

Walker Chandiok &..Co LLP

Welker Chandlok a Co LLP 21" Floor, DLF Square Jacaranda Marg, DLF Phase II Gurugram -122 002 India

T +91124 4628099 F +91 124 4628001

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Pfizer Limited

• 1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of Pfizer Limited ('the Company') for the quarter ended 30 June 2021, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). including relevant circulars issued by the SEBI from time to time
• 1. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review
• 1. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

C111rttrld Accounllnto Wtlktr Chlndiok l CO ll.P IS fl&ISCered With llmh.td li.bdity w~th ident1fbtfon ~"'be' 1-.N:· 208S ind IU rw111terwd office et l""41 r.or.r1•t..&nl CJn:l>s, New Oolhl, 110001, lndl•

Walker Chandiok &.Co LLP

4 Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act. and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No: 001076N/N500013

,Q

Ashish Gupta Partner Membership No. 504662

UDIN: 21504662AAAAFQ6188

Place: New Delhi Date: 28 July 2021 Pfizer Limited The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

Statement of Unaudited Financial Results for the Quarter ended 30th June 2021

			( ` in crore except earnings per share)
	3 months ended	Preceding 3	Corresponding 3	Year to date
	30/06/2021	months ended	months ended in	figures for
		31/03/2021	the previous year 30/06/2020	current year ended
				31/03/2021
Particulars	Unaudited	Audited	Unaudited	Audited
1 Income
(a) Revenue from operations	749.17	534.76	514.89	2,238.55
(b) Other income	12.24	37.20	17.20	81.12
Total income	761.41	571.96	532.09	2,319.67
2 Expenses
(a) Cost of materials consumed	94.50	87.37	73.30	334.74
(b) Purchases of stock-in-trade	162.29	43.15	121.96	448.65
(c) Changes in inventory of finished goods, work-in-progress and
stock-in-trade	17.73	65.25	(17.67)	14.35
(d) Employee benefits expense	94.36	94.83	85.90	361.06
(e) Finance costs	2.25	3.54	3.01	15.11
(f) Depreciation and amortization expense	27.00	27.31	27.14	109.41
(g) Other expenses	94.55	118.42	65.11	367.63
Total expenses	492.68	439.87	358.75	1,650.95
3 Profit before tax (1 - 2)	268.73	132.09	173.34	668.72
4 Tax expense
(a) Current tax	70.79	39.07	50.04	183.63
(b) Deferred tax	(1.97)	(7.53)	(1.15)	(12.52)
5 Net profit for the period / year (3 - 4)	199.91	100.55	124.45	497.61
6 Other comprehensive income
(a) Items that will not be reclassified subsequently to profit or loss	0.20	7.53	(2.94)	(1.28)
(b) Income tax related to items that will not be reclassified to profit or loss	(0.05)	(1.90)	0.74	0.32
Other comprehensive income, net of taxes	0.15	5.63	(2.20)	(0.96)
7 Total comprehensive income for the period / year (5 + 6)	200.06	106.18	122.25	496.65
8 Paid-up equity share capital (Face value per share `10)	45.75	45.75	45.75	45.75
9 Other equity				2,347.29
10 Earnings per share - Basic and Diluted (of `10/- each) Computed on the basis of net profit for the period / year	43.69*	21.98*	27.20*	108.77

*Earnings per share - Basic and Diluted (of `10/- each) not annualised

CIN: L24231MH1950PLC008311 Email ID: contactus.india@pfizer.com Website: www.pfizerindia.com

NOTES:

• 1. The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its Meeting held on July 28, 2021 and were approved and taken on record at the Meeting of the Board of Directors of the Company held on that date.
• 1. The financial results of the Company have been prepared in accordance with Indian Accounting Standards ('Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated July 5, 2016.
• 1. The financial results for the quarter ended June 30, 2021 have been subjected to limited review by the statutory auditors of the Company. The limited review report does not contain any modifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company's website - www.pfizerindia.com
• 1. Figures for the quarter ended March 31, 2021 represent the difference between the audited figures in respect of the full financial year and published figures of nine months ended December 31, 2020 which were subject to a limited review by the statutory auditors.
• 1. The Company has only one segment which is 'Pharmaceuticals'. Therefore disclosure relating to segments is not applicable and accordingly not made.
• 1. The Company has monitored the impact of COVID-19 on all aspects of its business. The management has exercised due care, in concluding on significant accounting judgements and estimates, recoverability of receivables, assessment for impairment of goodwill, intangible assets, inventory based on the information available as on date, while preparing the financial results as of June 30, 2021.

For Pfizer Limited

S. Sridhar July 28, 2021 Managing Director